lymphoma daudi Search Results


daudi  (ATCC)
95
ATCC daudi
Daudi, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lymphoma+daudi/Daudi%3B+Burkitt's+Lymphoma%3B+Human/pmc00109906-90-15-16
Average 95 stars, based on 1 article reviews
daudi - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

94
TaKaRa daudi
Daudi, supplied by TaKaRa, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lymphoma+daudi/Human+Lymphoma%2C+Burkitt's+(Daudi)+Poly+A%2B+RNA/us07772365-1201-30-34
Average 94 stars, based on 1 article reviews
daudi - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

90
BioResource International Inc lymphoblastoid cell lines
Sequenom MassARRAY methylation data of (A) normal, somatic tissues, and (B) <t>lymphoblastoid</t> cell lines (95% confidence intervals are shown). (C) TES expression levels by quantitative RT-PCR were calculated relative to B2M expression and normalised to relative expression levels in the normal peripheral blood leukocyte sample (PBL2) (error bars are standard deviations).
Lymphoblastoid Cell Lines, supplied by BioResource International Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lymphoma+daudi/b+cell+lymphoma+cell+lines+daudi/pmc04795691-62-0-13
Average 90 stars, based on 1 article reviews
lymphoblastoid cell lines - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Beijing Xiehe Pharmaceutical Co Ltd hek293t cells
(A) Schematic diagram of m 6 A detection with DART-seq in cultured cells. The YTH protein domain binds to m 6 A. When bound to APOBEC1, the APOBEC1 protein converts C-to-U in the vicinity of m 6 A. This results in a C-to-T mutation in cDNA. C-to-T mutations detected by RNA sequencing are indicative of m 6 A RNA modifications. (B) Left: Immunofluorescence (IF) of <t>HEK293T</t> cells transfected with Apobec1-Yth-HA- Egfp ( Yth-HA-E ) or Egfp-Apobec1-Yth-HA (E-YTH-HA ). Scale bar, 20μm, representative images are shown. Right: Quantification of EGFP and HA overlap. PCC: Pearson’s Correlation Coefficient. (C) Number of C-to-T editing events identified in each bulk DART-seq HEK293T cell replicate for Yth-E and E-Yth plasmids. Editing events identified in at least 2 replicates were considered for downstream analyses. The data was obtained following Apobec1-Yth-Egfp or Egfp-Apobec1-Yth transfection and EGFP FACS sorting. n=3, Rep: separately cultured replicate. (D) Metagene analysis showing m 6 A site counts along transcripts for Yth-E and E-Yth DART-seq results. 9% of all m 6 A sites occur in the first 10% of the 3’ UTR following the TTS for YTH-E, and 11% for E-YTH, respectively. Shown percentage indicates number of m 6 A sites upstream, within and downstream of coding sequence (CDS). (E) Metagene analysis showing m 6 A density 500nt 5’ and 500nt 3’ from stop codon (0nt) for YTH-E and E-YTH.
Hek293t Cells, supplied by Beijing Xiehe Pharmaceutical Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lymphoma+daudi/lymphoma+cell+line+daudi/bio_rxiv__2023__12__06__570314-225-0-5
Average 90 stars, based on 1 article reviews
hek293t cells - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
CEM Corporation burkitt lymphoma daudi
(A) Schematic diagram of m 6 A detection with DART-seq in cultured cells. The YTH protein domain binds to m 6 A. When bound to APOBEC1, the APOBEC1 protein converts C-to-U in the vicinity of m 6 A. This results in a C-to-T mutation in cDNA. C-to-T mutations detected by RNA sequencing are indicative of m 6 A RNA modifications. (B) Left: Immunofluorescence (IF) of <t>HEK293T</t> cells transfected with Apobec1-Yth-HA- Egfp ( Yth-HA-E ) or Egfp-Apobec1-Yth-HA (E-YTH-HA ). Scale bar, 20μm, representative images are shown. Right: Quantification of EGFP and HA overlap. PCC: Pearson’s Correlation Coefficient. (C) Number of C-to-T editing events identified in each bulk DART-seq HEK293T cell replicate for Yth-E and E-Yth plasmids. Editing events identified in at least 2 replicates were considered for downstream analyses. The data was obtained following Apobec1-Yth-Egfp or Egfp-Apobec1-Yth transfection and EGFP FACS sorting. n=3, Rep: separately cultured replicate. (D) Metagene analysis showing m 6 A site counts along transcripts for Yth-E and E-Yth DART-seq results. 9% of all m 6 A sites occur in the first 10% of the 3’ UTR following the TTS for YTH-E, and 11% for E-YTH, respectively. Shown percentage indicates number of m 6 A sites upstream, within and downstream of coding sequence (CDS). (E) Metagene analysis showing m 6 A density 500nt 5’ and 500nt 3’ from stop codon (0nt) for YTH-E and E-YTH.
Burkitt Lymphoma Daudi, supplied by CEM Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lymphoma+daudi/burkitt+lymphoma+daudi/pmc01508076-113-47-56
Average 90 stars, based on 1 article reviews
burkitt lymphoma daudi - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Procell Inc pbmc and b lymphoma cell lines daudi
(A) Survival analyses of GSE10846 (n = 420) in DLBCL patients with high and low expression of SNHG17.(B, C) Kaplan–Meier survival analysis. (D, E) Uniform and multivariate expression analyses (all bars correspond to the 95% confidence intervals). (F) Nomogram was used to predict the OS of patients. (G) Expression of SNHG17 in DLBCL patients’ tumor and normal tissues.The sequencing data for normal cells and diffuse large <t>B-cell</t> <t>lymphoma</t> were obtained from UCSC XENA, which we have described in the methods section. (H) qPCR shows the expression of SNHG17 in lymphoma cell lines (Daudi, Ramos, DoHH2, Farage, and Raji) and peripheral blood mononuclear cells <t>(PBMC).*P</t> < 0.05, **P < 0.01, ***P < 0.001.
Pbmc And B Lymphoma Cell Lines Daudi, supplied by Procell Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lymphoma+daudi/pbmc+and+b+lymphoma+cell+lines+daudi/pmc10662735-61-0-15
Average 90 stars, based on 1 article reviews
pbmc and b lymphoma cell lines daudi - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
European Collection of Authenticated Cell Cultures daudi b-cell lymphoma line
V δ 2 + γδ T cells release granulysin in response to tumour. (a) The expression of exhaustion markers PD‐1 and Lag‐3 on, and the secretion of granulysin by, V δ 2 + γδ T cells during the 9‐day expansion process. (b) The percentage of V δ 2 + γδ T cells to express early activation marker CD69 following 24, 48 or 72 hr of culture with <t>Daudi</t> <t>cells,</t> <t>Raji</t> cells or Raji cells pre‐treated for 24 hr with 5 μ m zoledronic acid (ZA), as determined by flow cytometry. (c) The concentration of interferon‐ γ (IFN‐ γ ) found within supernatants taken from 24, 48 or 72 hr co‐culture of V δ 2 + γδ T cells with tumour cell lines, as determined by ELISA. (d) The percentage of V δ 2 + γδ T cells to express degranulation marker CD107a following 24, 48 or 72 hr of culture with Daudi cells, Raji cells or Raji cells pre‐treated for 24 hr with 5 μ m ZA, as determined by flow cytometry. (e) The concentration of granulysin found within supernatants taken from 24, 48 or 72 hr co‐culture of V δ 2 + γδ T cells with tumour cell lines, as determined by ELISA. (f) The concentration of granzyme B found within supernatants taken from 24, 48 or 72 hr co‐culture of V δ 2 + γδ T cells with tumour cell lines, as determined by ELISA. (g) Percentage killing of tumour cells by V δ 2 + γδ T cells following 24, 48 and 72 hr of culture, as determined by flow cytometry. Data shown are from six independent experiments, using V δ 2 + γδ T cells from six individual donors, with error bars (SD). Differences between groups were assessed by two‐way analysis of variance comparing negative control (V δ 2 + γδ T cells alone) with all other groups. * P < 0·05. ** P < 0·01. *** P < 0·001. **** P < 0·0001.
Daudi B Cell Lymphoma Line, supplied by European Collection of Authenticated Cell Cultures, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lymphoma+daudi/daudi+b+cell+lymphoma+line/pmc07576882-40-0-6
Average 90 stars, based on 1 article reviews
daudi b-cell lymphoma line - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Obio Technology Corp Ltd b cell lymphoma cell lines raji and daudi
BTZ@HMSNs restricts the proliferation <t>of</t> <t>lymphoma.</t> ( A ) Cell viability of SNK-1 cells treated with PBS (control), HMSNs, BTZ (set from 1 to 150 nM), HMSNs+BTZ (containing 1-150 nM of BTZ) and BTZ@HMSNs (containing 1-150 nM of BTZ) by MTT assay. ( B ) The gene expression profile of <t>Daudi,</t> Jurkat, Raji, SNK-1 and NK92 cells by qRT-PCR (Left). Cell viability of indicated cells treated with BTZ or BTZ@HMSNs by MTT assay (Right). ( C ) Colony number of SNK-1 cells treated with PBS (control), HMSNs, BTZ, BTZ@HMSNs by colony formation assay. BTZ, bortezomib; HMSNs, hollow mesoporous silica nanospheres. The differences between groups were analyzed by one-way ANOVA followed by multiple comparison with Tukey test. ** P < 0.01 and *** P < 0.001. Values are means ± SD.
B Cell Lymphoma Cell Lines Raji And Daudi, supplied by Obio Technology Corp Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lymphoma+daudi/b+cell+lymphoma+cell+lines+raji+and+daudi/pmc07835069-132-15-20
Average 90 stars, based on 1 article reviews
b cell lymphoma cell lines raji and daudi - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
National Centre for Cell Science ebv-positive burkitt’s lymphoma cell line raji
BTZ@HMSNs restricts the proliferation <t>of</t> <t>lymphoma.</t> ( A ) Cell viability of SNK-1 cells treated with PBS (control), HMSNs, BTZ (set from 1 to 150 nM), HMSNs+BTZ (containing 1-150 nM of BTZ) and BTZ@HMSNs (containing 1-150 nM of BTZ) by MTT assay. ( B ) The gene expression profile of <t>Daudi,</t> Jurkat, Raji, SNK-1 and NK92 cells by qRT-PCR (Left). Cell viability of indicated cells treated with BTZ or BTZ@HMSNs by MTT assay (Right). ( C ) Colony number of SNK-1 cells treated with PBS (control), HMSNs, BTZ, BTZ@HMSNs by colony formation assay. BTZ, bortezomib; HMSNs, hollow mesoporous silica nanospheres. The differences between groups were analyzed by one-way ANOVA followed by multiple comparison with Tukey test. ** P < 0.01 and *** P < 0.001. Values are means ± SD.
Ebv Positive Burkitt’s Lymphoma Cell Line Raji, supplied by National Centre for Cell Science, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lymphoma+daudi/human+burkitt%E2%80%99s+lymphoma+cell+lines++raji+and+daudi/pmc07472350-46-1-29
Average 90 stars, based on 1 article reviews
ebv-positive burkitt’s lymphoma cell line raji - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
BioResource International Inc daudi cells b lymphoblast cell line from a burkitt lymphoma patient
BTZ@HMSNs restricts the proliferation <t>of</t> <t>lymphoma.</t> ( A ) Cell viability of SNK-1 cells treated with PBS (control), HMSNs, BTZ (set from 1 to 150 nM), HMSNs+BTZ (containing 1-150 nM of BTZ) and BTZ@HMSNs (containing 1-150 nM of BTZ) by MTT assay. ( B ) The gene expression profile of <t>Daudi,</t> Jurkat, Raji, SNK-1 and NK92 cells by qRT-PCR (Left). Cell viability of indicated cells treated with BTZ or BTZ@HMSNs by MTT assay (Right). ( C ) Colony number of SNK-1 cells treated with PBS (control), HMSNs, BTZ, BTZ@HMSNs by colony formation assay. BTZ, bortezomib; HMSNs, hollow mesoporous silica nanospheres. The differences between groups were analyzed by one-way ANOVA followed by multiple comparison with Tukey test. ** P < 0.01 and *** P < 0.001. Values are means ± SD.
Daudi Cells B Lymphoblast Cell Line From A Burkitt Lymphoma Patient, supplied by BioResource International Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lymphoma+daudi/daudi+cells+b+lymphoblast+cell+line+from+a+burkitt+lymphoma+patient/pm37310262-80-0-15
Average 90 stars, based on 1 article reviews
daudi cells b lymphoblast cell line from a burkitt lymphoma patient - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Cosman Medical burkitt's lymphoma b cell line transfected to express β 2 microglobulin daudi/class i
BTZ@HMSNs restricts the proliferation <t>of</t> <t>lymphoma.</t> ( A ) Cell viability of SNK-1 cells treated with PBS (control), HMSNs, BTZ (set from 1 to 150 nM), HMSNs+BTZ (containing 1-150 nM of BTZ) and BTZ@HMSNs (containing 1-150 nM of BTZ) by MTT assay. ( B ) The gene expression profile of <t>Daudi,</t> Jurkat, Raji, SNK-1 and NK92 cells by qRT-PCR (Left). Cell viability of indicated cells treated with BTZ or BTZ@HMSNs by MTT assay (Right). ( C ) Colony number of SNK-1 cells treated with PBS (control), HMSNs, BTZ, BTZ@HMSNs by colony formation assay. BTZ, bortezomib; HMSNs, hollow mesoporous silica nanospheres. The differences between groups were analyzed by one-way ANOVA followed by multiple comparison with Tukey test. ** P < 0.01 and *** P < 0.001. Values are means ± SD.
Burkitt's Lymphoma B Cell Line Transfected To Express β 2 Microglobulin Daudi/Class I, supplied by Cosman Medical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lymphoma+daudi/burkitt+s+lymphoma+b+cell+line+transfected+to+express+%CE%B2+2+microglobulin+daudi+class+i/pmc01305038-232-9-19
Average 90 stars, based on 1 article reviews
burkitt's lymphoma b cell line transfected to express β 2 microglobulin daudi/class i - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Charles River Laboratories daudi lymphoma cells
Tcl1 and Atm are crucial for growth and proliferation <t>of</t> <t>lymphoma</t> cells in vitro and in vivo. (A) <t>Daudi</t> cells were mock-transfected or transfected with si-TCL1 or si-Scr and then untreated or treated with Kudos 55933 or DMSO. Cells were counted at 24-hour intervals. Results represent the average of 3 independent experiments. (B) Total lysates collected were analyzed by Western blot and tested with indicated antibodies. (C) Graph representing tumor volumes at indicated days during the experiment for the 5 groups indicated (4 mice/group). Tumor size was measured daily until the tumor reached 50 mm3. Then, 5 μg of synthetic si-TCL1or si-Scr diluted in Lipofectamine and with or without Kudos (50 μL total volume) were injected directly into the tumors and at 3, 7, and 10 days. Tumors were measured on the day of the injections and 4 days after the last injection. (D) Total lysates from tumors were analyzed by Western blot and tested with indicated antibodies. (E) Xenograft tumors were weighed. Data are mean ± SEM of 3 independent experiments, and each is measured in triplicate. *P < .05.
Daudi Lymphoma Cells, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lymphoma+daudi/daudi+lymphoma+cells/pmc03251228-93-5-29
Average 90 stars, based on 1 article reviews
daudi lymphoma cells - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


Sequenom MassARRAY methylation data of (A) normal, somatic tissues, and (B) lymphoblastoid cell lines (95% confidence intervals are shown). (C) TES expression levels by quantitative RT-PCR were calculated relative to B2M expression and normalised to relative expression levels in the normal peripheral blood leukocyte sample (PBL2) (error bars are standard deviations).

Journal: PLoS ONE

Article Title: TESTIN Induces Rapid Death and Suppresses Proliferation in Childhood B Acute Lymphoblastic Leukaemia Cells

doi: 10.1371/journal.pone.0151341

Figure Lengend Snippet: Sequenom MassARRAY methylation data of (A) normal, somatic tissues, and (B) lymphoblastoid cell lines (95% confidence intervals are shown). (C) TES expression levels by quantitative RT-PCR were calculated relative to B2M expression and normalised to relative expression levels in the normal peripheral blood leukocyte sample (PBL2) (error bars are standard deviations).

Article Snippet: Lymphoblastoid cell lines were cultured as recommended by the ATCC or the RIKEN BioResource Center.

Techniques: Methylation, Expressing, Quantitative RT-PCR

(A) Schematic diagram of m 6 A detection with DART-seq in cultured cells. The YTH protein domain binds to m 6 A. When bound to APOBEC1, the APOBEC1 protein converts C-to-U in the vicinity of m 6 A. This results in a C-to-T mutation in cDNA. C-to-T mutations detected by RNA sequencing are indicative of m 6 A RNA modifications. (B) Left: Immunofluorescence (IF) of HEK293T cells transfected with Apobec1-Yth-HA- Egfp ( Yth-HA-E ) or Egfp-Apobec1-Yth-HA (E-YTH-HA ). Scale bar, 20μm, representative images are shown. Right: Quantification of EGFP and HA overlap. PCC: Pearson’s Correlation Coefficient. (C) Number of C-to-T editing events identified in each bulk DART-seq HEK293T cell replicate for Yth-E and E-Yth plasmids. Editing events identified in at least 2 replicates were considered for downstream analyses. The data was obtained following Apobec1-Yth-Egfp or Egfp-Apobec1-Yth transfection and EGFP FACS sorting. n=3, Rep: separately cultured replicate. (D) Metagene analysis showing m 6 A site counts along transcripts for Yth-E and E-Yth DART-seq results. 9% of all m 6 A sites occur in the first 10% of the 3’ UTR following the TTS for YTH-E, and 11% for E-YTH, respectively. Shown percentage indicates number of m 6 A sites upstream, within and downstream of coding sequence (CDS). (E) Metagene analysis showing m 6 A density 500nt 5’ and 500nt 3’ from stop codon (0nt) for YTH-E and E-YTH.

Journal: bioRxiv

Article Title: Single cell discovery of m 6 A RNA modifications in the hippocampus

doi: 10.1101/2023.12.06.570314

Figure Lengend Snippet: (A) Schematic diagram of m 6 A detection with DART-seq in cultured cells. The YTH protein domain binds to m 6 A. When bound to APOBEC1, the APOBEC1 protein converts C-to-U in the vicinity of m 6 A. This results in a C-to-T mutation in cDNA. C-to-T mutations detected by RNA sequencing are indicative of m 6 A RNA modifications. (B) Left: Immunofluorescence (IF) of HEK293T cells transfected with Apobec1-Yth-HA- Egfp ( Yth-HA-E ) or Egfp-Apobec1-Yth-HA (E-YTH-HA ). Scale bar, 20μm, representative images are shown. Right: Quantification of EGFP and HA overlap. PCC: Pearson’s Correlation Coefficient. (C) Number of C-to-T editing events identified in each bulk DART-seq HEK293T cell replicate for Yth-E and E-Yth plasmids. Editing events identified in at least 2 replicates were considered for downstream analyses. The data was obtained following Apobec1-Yth-Egfp or Egfp-Apobec1-Yth transfection and EGFP FACS sorting. n=3, Rep: separately cultured replicate. (D) Metagene analysis showing m 6 A site counts along transcripts for Yth-E and E-Yth DART-seq results. 9% of all m 6 A sites occur in the first 10% of the 3’ UTR following the TTS for YTH-E, and 11% for E-YTH, respectively. Shown percentage indicates number of m 6 A sites upstream, within and downstream of coding sequence (CDS). (E) Metagene analysis showing m 6 A density 500nt 5’ and 500nt 3’ from stop codon (0nt) for YTH-E and E-YTH.

Article Snippet: HEK293T cells were purchased from Beijing Xiehe Cell Bank and cultured at 37°C with 5% CO2 in DMEM (Dulbecco’s Modified Eagle Medium) containing 10% FBS and 1% penicillin/streptomycin.

Techniques: Cell Culture, Mutagenesis, RNA Sequencing, Immunofluorescence, Transfection, Sequencing

(A) Survival analyses of GSE10846 (n = 420) in DLBCL patients with high and low expression of SNHG17.(B, C) Kaplan–Meier survival analysis. (D, E) Uniform and multivariate expression analyses (all bars correspond to the 95% confidence intervals). (F) Nomogram was used to predict the OS of patients. (G) Expression of SNHG17 in DLBCL patients’ tumor and normal tissues.The sequencing data for normal cells and diffuse large B-cell lymphoma were obtained from UCSC XENA, which we have described in the methods section. (H) qPCR shows the expression of SNHG17 in lymphoma cell lines (Daudi, Ramos, DoHH2, Farage, and Raji) and peripheral blood mononuclear cells (PBMC).*P < 0.05, **P < 0.01, ***P < 0.001.

Journal: PLOS ONE

Article Title: Long non-coding RNA SNHG17 may function as a competitive endogenous RNA in diffuse large B-cell lymphoma progression by sponging miR-34a-5p

doi: 10.1371/journal.pone.0294729

Figure Lengend Snippet: (A) Survival analyses of GSE10846 (n = 420) in DLBCL patients with high and low expression of SNHG17.(B, C) Kaplan–Meier survival analysis. (D, E) Uniform and multivariate expression analyses (all bars correspond to the 95% confidence intervals). (F) Nomogram was used to predict the OS of patients. (G) Expression of SNHG17 in DLBCL patients’ tumor and normal tissues.The sequencing data for normal cells and diffuse large B-cell lymphoma were obtained from UCSC XENA, which we have described in the methods section. (H) qPCR shows the expression of SNHG17 in lymphoma cell lines (Daudi, Ramos, DoHH2, Farage, and Raji) and peripheral blood mononuclear cells (PBMC).*P < 0.05, **P < 0.01, ***P < 0.001.

Article Snippet: PBMC and B lymphoma cell lines (Daudi, Ramos, DoHH2, Farage, and Raji) were purchased from Procell (Nanjing Cobioer Biosciences Co, LTD, China) and cultured in a 1640 Roswell Park Memorial Institute (RPMI-1640) medium containing 10% fetal bovine serum.

Techniques: Expressing, Sequencing

V δ 2 + γδ T cells release granulysin in response to tumour. (a) The expression of exhaustion markers PD‐1 and Lag‐3 on, and the secretion of granulysin by, V δ 2 + γδ T cells during the 9‐day expansion process. (b) The percentage of V δ 2 + γδ T cells to express early activation marker CD69 following 24, 48 or 72 hr of culture with Daudi cells, Raji cells or Raji cells pre‐treated for 24 hr with 5 μ m zoledronic acid (ZA), as determined by flow cytometry. (c) The concentration of interferon‐ γ (IFN‐ γ ) found within supernatants taken from 24, 48 or 72 hr co‐culture of V δ 2 + γδ T cells with tumour cell lines, as determined by ELISA. (d) The percentage of V δ 2 + γδ T cells to express degranulation marker CD107a following 24, 48 or 72 hr of culture with Daudi cells, Raji cells or Raji cells pre‐treated for 24 hr with 5 μ m ZA, as determined by flow cytometry. (e) The concentration of granulysin found within supernatants taken from 24, 48 or 72 hr co‐culture of V δ 2 + γδ T cells with tumour cell lines, as determined by ELISA. (f) The concentration of granzyme B found within supernatants taken from 24, 48 or 72 hr co‐culture of V δ 2 + γδ T cells with tumour cell lines, as determined by ELISA. (g) Percentage killing of tumour cells by V δ 2 + γδ T cells following 24, 48 and 72 hr of culture, as determined by flow cytometry. Data shown are from six independent experiments, using V δ 2 + γδ T cells from six individual donors, with error bars (SD). Differences between groups were assessed by two‐way analysis of variance comparing negative control (V δ 2 + γδ T cells alone) with all other groups. * P < 0·05. ** P < 0·01. *** P < 0·001. **** P < 0·0001.

Journal: Immunology

Article Title: The cytotoxic molecule granulysin is capable of inducing either chemotaxis or fugetaxis in dendritic cells depending on maturation: a role for V δ 2 + γδ T cells in the modulation of immune response to tumour?

doi: 10.1111/imm.13248

Figure Lengend Snippet: V δ 2 + γδ T cells release granulysin in response to tumour. (a) The expression of exhaustion markers PD‐1 and Lag‐3 on, and the secretion of granulysin by, V δ 2 + γδ T cells during the 9‐day expansion process. (b) The percentage of V δ 2 + γδ T cells to express early activation marker CD69 following 24, 48 or 72 hr of culture with Daudi cells, Raji cells or Raji cells pre‐treated for 24 hr with 5 μ m zoledronic acid (ZA), as determined by flow cytometry. (c) The concentration of interferon‐ γ (IFN‐ γ ) found within supernatants taken from 24, 48 or 72 hr co‐culture of V δ 2 + γδ T cells with tumour cell lines, as determined by ELISA. (d) The percentage of V δ 2 + γδ T cells to express degranulation marker CD107a following 24, 48 or 72 hr of culture with Daudi cells, Raji cells or Raji cells pre‐treated for 24 hr with 5 μ m ZA, as determined by flow cytometry. (e) The concentration of granulysin found within supernatants taken from 24, 48 or 72 hr co‐culture of V δ 2 + γδ T cells with tumour cell lines, as determined by ELISA. (f) The concentration of granzyme B found within supernatants taken from 24, 48 or 72 hr co‐culture of V δ 2 + γδ T cells with tumour cell lines, as determined by ELISA. (g) Percentage killing of tumour cells by V δ 2 + γδ T cells following 24, 48 and 72 hr of culture, as determined by flow cytometry. Data shown are from six independent experiments, using V δ 2 + γδ T cells from six individual donors, with error bars (SD). Differences between groups were assessed by two‐way analysis of variance comparing negative control (V δ 2 + γδ T cells alone) with all other groups. * P < 0·05. ** P < 0·01. *** P < 0·001. **** P < 0·0001.

Article Snippet: Daudi and Raji B‐cell lymphoma lines (European Collection of Authenticated Cell Cultures, Salisbury, UK) were used in experiments as γδ T‐cell‐susceptible and ‐resistant target cells, respectively.

Techniques: Expressing, Activation Assay, Marker, Flow Cytometry, Concentration Assay, Co-Culture Assay, Enzyme-linked Immunosorbent Assay, Negative Control

BTZ@HMSNs restricts the proliferation of lymphoma. ( A ) Cell viability of SNK-1 cells treated with PBS (control), HMSNs, BTZ (set from 1 to 150 nM), HMSNs+BTZ (containing 1-150 nM of BTZ) and BTZ@HMSNs (containing 1-150 nM of BTZ) by MTT assay. ( B ) The gene expression profile of Daudi, Jurkat, Raji, SNK-1 and NK92 cells by qRT-PCR (Left). Cell viability of indicated cells treated with BTZ or BTZ@HMSNs by MTT assay (Right). ( C ) Colony number of SNK-1 cells treated with PBS (control), HMSNs, BTZ, BTZ@HMSNs by colony formation assay. BTZ, bortezomib; HMSNs, hollow mesoporous silica nanospheres. The differences between groups were analyzed by one-way ANOVA followed by multiple comparison with Tukey test. ** P < 0.01 and *** P < 0.001. Values are means ± SD.

Journal: Aging (Albany NY)

Article Title: The improved anticancer effects of Bortezomib-loaded hollow mesoporous silica nanospheres on lymphoma development

doi: 10.18632/aging.202146

Figure Lengend Snippet: BTZ@HMSNs restricts the proliferation of lymphoma. ( A ) Cell viability of SNK-1 cells treated with PBS (control), HMSNs, BTZ (set from 1 to 150 nM), HMSNs+BTZ (containing 1-150 nM of BTZ) and BTZ@HMSNs (containing 1-150 nM of BTZ) by MTT assay. ( B ) The gene expression profile of Daudi, Jurkat, Raji, SNK-1 and NK92 cells by qRT-PCR (Left). Cell viability of indicated cells treated with BTZ or BTZ@HMSNs by MTT assay (Right). ( C ) Colony number of SNK-1 cells treated with PBS (control), HMSNs, BTZ, BTZ@HMSNs by colony formation assay. BTZ, bortezomib; HMSNs, hollow mesoporous silica nanospheres. The differences between groups were analyzed by one-way ANOVA followed by multiple comparison with Tukey test. ** P < 0.01 and *** P < 0.001. Values are means ± SD.

Article Snippet: Human NK cell lymphoma cell line SNK-1 and B cell lymphoma cell lines Raji and Daudi were obtained from Shanghai Obio Technology Co., Ltd (China), and T cell lymphoma cell line Jurkat and NK cell lymphoma cell line NK-92 were purchased from the American Type Culture Collection (ATCC).

Techniques: Control, MTT Assay, Gene Expression, Quantitative RT-PCR, Colony Assay, Comparison

Tcl1 and Atm are crucial for growth and proliferation of lymphoma cells in vitro and in vivo. (A) Daudi cells were mock-transfected or transfected with si-TCL1 or si-Scr and then untreated or treated with Kudos 55933 or DMSO. Cells were counted at 24-hour intervals. Results represent the average of 3 independent experiments. (B) Total lysates collected were analyzed by Western blot and tested with indicated antibodies. (C) Graph representing tumor volumes at indicated days during the experiment for the 5 groups indicated (4 mice/group). Tumor size was measured daily until the tumor reached 50 mm3. Then, 5 μg of synthetic si-TCL1or si-Scr diluted in Lipofectamine and with or without Kudos (50 μL total volume) were injected directly into the tumors and at 3, 7, and 10 days. Tumors were measured on the day of the injections and 4 days after the last injection. (D) Total lysates from tumors were analyzed by Western blot and tested with indicated antibodies. (E) Xenograft tumors were weighed. Data are mean ± SEM of 3 independent experiments, and each is measured in triplicate. *P < .05.

Journal: Blood

Article Title: Tcl1 interacts with Atm and enhances NF-κB activation in hematologic malignancies

doi: 10.1182/blood-2011-08-374561

Figure Lengend Snippet: Tcl1 and Atm are crucial for growth and proliferation of lymphoma cells in vitro and in vivo. (A) Daudi cells were mock-transfected or transfected with si-TCL1 or si-Scr and then untreated or treated with Kudos 55933 or DMSO. Cells were counted at 24-hour intervals. Results represent the average of 3 independent experiments. (B) Total lysates collected were analyzed by Western blot and tested with indicated antibodies. (C) Graph representing tumor volumes at indicated days during the experiment for the 5 groups indicated (4 mice/group). Tumor size was measured daily until the tumor reached 50 mm3. Then, 5 μg of synthetic si-TCL1or si-Scr diluted in Lipofectamine and with or without Kudos (50 μL total volume) were injected directly into the tumors and at 3, 7, and 10 days. Tumors were measured on the day of the injections and 4 days after the last injection. (D) Total lysates from tumors were analyzed by Western blot and tested with indicated antibodies. (E) Xenograft tumors were weighed. Data are mean ± SEM of 3 independent experiments, and each is measured in triplicate. *P < .05.

Article Snippet: Tumors were established by injecting Daudi lymphoma cells (200 μL PBS, 7.5 × 10 7 cells/mouse) into the right flanks of female nude mice at 6 weeks of age (Charles River Breeding Laboratories).

Techniques: In Vitro, In Vivo, Transfection, Western Blot, Injection